Moving past "one Size (and Number) Fits All" in the selection of candidates with hepatocellular carcinoma for liver transplantation

Liver Transplantation

Volumn 19, Issue 10, 2013, Pages 1055-1058

  Mehta, Neil ^a   Yao, Francis Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; EUROPE; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84884874721     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23730     Document Type: Review

References (22)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
2. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
3. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596.
4. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509.
5. Yao FY,. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-1989.
6. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M,. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011; 17 (suppl 2): S72-S80.
7. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.; for Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
8. Berry K, Ioannou GN,. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645.
9. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
10. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
11. Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011; 146: 26-33.
12. Hameed B, Sapisochin G, Roberts JP, Yao FY,. Alpha-fetoprotein >1000 ng/mL as an exclusion criteria for liver transplant in patients with hepatocellular carcinoma meeting Milan criteria [abstract]. Hepatology 2011; 54 (suppl 1): 414A.
13. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR,. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-999.
14. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.
15. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
16. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279.
17. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M,. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011; 17 (suppl 2): S109-S116.
18. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al.; for European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified Response Evaluation Criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118.
19. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
20. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY,. Identification of liver transplant candidates with hepatocellular carcinoma and very low dropout risk: implications for the current organ allocation policy. Liver Transpl. In press.
21. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
22. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, et al. Pretransplantation α-fetoprotein slope and Milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013; 95: 228-233.